One promising series of small-molecule orexin receptor agonists has been described, but the molecular pharmacological properties, i.e. ability and potency to activate the different orexin receptor-regulated signal pathways have not been reported for any of these ligands. We have thus here assessed these properties for the most potent ligand of the series, 4′-methoxy-
Introduction
Orexin-A and -B are hypothalamic neuropeptides that have been most strongly associated with regulation of sleep and wakefulness (reviewed in Li et al., 2017; Scammell et al., 2017) . This is most clearly seen in narcolepsy; death of orexinergic neurons is thought to lie behind human narcolepsy (Nishino et al., 2000) , and narcoleptic phenotype is seen in animals upon genetic destruction of orexinergic neurons, orexin peptides or orexin receptors, or toxic destruction of orexin target neurons (Chemelli et al., 1999; Lin et al., 1999; Hara et al., 2001; Gerashchenko et al., 2001; Willie et al., 2003) . The orexin system has also been associated with other central physiological and pathophysiological functions, such as metabolic regulation, feeding, stress response, addiction and pain gating (reviewed in Kukkonen, 2013; Baimel et al., 2015) , and orexin receptor polymorphisms have been and are investigated with respect to additional indications such as anxiety and depression (reviewed in Thompson et al., 2014) . It can thus be assumed that both orexin receptor antagonists and agonists might be useful in different types of disorders. Orexin receptor antagonist discovery is currently mainly focusing on the development of hypnotics (reviewed in Roecker et al., 2016) ; one such drug, suvorexant, is already on the market in the US and Japan. Orexin receptor agonists, on the other hand, would find an obvious use in narcolepsy − a concept that has been proven in rodents (Mieda et al., 2004; Kantor et al., 2013; Irukayama-Tomobe et al., 2017 ) − as well as likely in other disorders of increased sleep and reduced vigilance. Other apparent, though thus far less substantiated, uses of the agonists would be in some metabolic disorders and some cancers; orexin receptor stimulation can also stimulate programmed cell death of some cancer cells (Rouet-Benzineb et al., 2004; Ammoun et al., 2006; Voisin et al., 2006 Voisin et al., , 2011 .
While orexin antagonist development has been very active and successful, little has happened on the agonist side. Only one potent series of small molecular weight orexin receptor agonists has been described (Nagahara et al., 2015) ; the other reported agonists appear to have low potency and possible low selectivity (see, e.g. Turku et al., 2016; Turku et al., 2017) . The pharmacological properties of even the promising series reported in (Nagahara et al., 2015) are barely known. We thus decided to characterized the most potent ligand of the series, 4′-methoxy-N,N-dimethyl-3′-[N-(3-{[2-(3-methylbenzamido) ethyl] amino}phenyl) sulfamoyl]-(1,1′-biphenyl)-3-carboxamide (compound 26; here referred as Nag 26), in the current study. The ligand was synthesized and its activity and potency with respect to a number of different responses, involving the three classical G-protein pathways, was assessed for both human orexin receptor subtypes expressed in Chinese hamster ovary K1 (CHO) cells.
Materials and methods

Materials
Human orexin-A was from NeoMPS (Strasbourg, France),
, thapsigargin and pertussis toxin from Tocris Bioscience (Bristol, UK), and cholera toxin, forskolin, staurosporin and 3-isobutyl-1-methylxanthine from Sigma-Aldrich. Hoechst 33342 [2′-(4-ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-1H,1′H-2,5′-bibenzimidazole; here abbreviated as Hoechst] was from Molecular Probes/Life Technologies (Carlsbad, CA, USA), 7, 168.6, 157.1, 150.4, 139.9, 139.4, 139.3, 138.6, 135.4, 134.3, 133.2, 133.0, 130.7, 130.0, 130.0, 129.3, 128.7, 128.4, 127.6, 126.9, 125.9, 125.1, 114.1, 110.3, 109.6, 104.5, 57.2, 44.0, 39.8, 39.7, 35.4, 21.4 
Cell culture and media
CHO-hOX 1 and -hOX 2 cells (Lund et al., 2000; Ammoun et al., 2003) as well as ctrl CHO-K1 cells (not expressing orexin receptors; ctrl CHO cells) were cultured in Ham's F12 medium (Gibco/Life Technologies, Paisley, UK) + supplements on plastic cell culture dishes (56 cm 2 bottom area; Greiner Bio-One GmbH, Frickenhausen, Germany) as described in (Jäntti et al., 2012) . Different types of multi-well plates were used for the assays: black, clear-bottom half-area Cellstar µClear 96-well cell culture plates (Greiner Bio-One GmbH) for Ca 2+ measurements; black, clear-bottom Cellstar µClear 96-well cell culture plates (Greiner) for cell death assays; and clear Cellstar 48-or 96-well cell culture plates (Greiner) for phospholipase C and adenylyl cyclase assays. All multi-well plates were coated with polyethyleneimine (25 μg/ml for 1 h at 37°C; Sigma-Aldrich, St. Louis, MO, USA). Cells were for the adenylyl cyclase experiments pretreated for 20 h with cholera toxin (1000 ng/ml) or for 36 h with pertussis toxin (300 ng/ml). Hepes-buffered medium (HBM) was used as the basic experimental medium. It was composed of 137 mM NaCl, 5 mM KCl, 1.2 mM MgCl 2 , 0.44 mM KH 2 PO 4 , 4.2 mM NaHCO 3 , 1 mM CaCl 2 , 10 mM glucose, 20 mM HEPES, and adjusted to pH 7.4 with NaOH.
Ca 2+ elevation
Ca 2+ elevations were measured as described before (Turku et al., 2017 Fig. 1AB ). Antagonists were manually added in the wells during the probe incubation (30 min before the measurement).
Phospholipase C activity
Phospholipase C activity was measured as described before (Turku et al., 2017) . Briefly, 1.1 × 10 4 or 2.4 × 10 4 cells per well were plated on clear 96-or 48-well plates, respectively. Twenty-four hours later, they were labelled with 3 µCi/ml [ 3 H]inositol for 20 h. The medium was removed, and the cells were incubated in HBM supplemented with 10 mM LiCl for 30 min at 37°C; also the possible inhibitors, TCS 1102 and L-threonine,
were included in this incubation. They were then stimulated with orexin-A or Nag 26 for 30 min, after which the medium was rapidly removed and the reactions stopped with ice-cold perchloric acid and freezing. The samples were thawed and neutralized, and the insoluble fragments spun down. The total inositol phosphate fraction of the supernatants was isolated by anion-exchange chromatography, and the radioactivity determined by scintillation counting (HiSafe 3 scintillation cocktail and Wallac 1415 liquid scintillation counter; PerkinElmer).
Adenylyl cyclase activity
Adenylyl cyclase activity was measured as described before (Turku et al., 2017) . Briefly, 2.4 × 10 4 (cholera toxin-treated) or 3.0 × 10 discarded and the reactions terminated with ice-cold perchloric acid and rapid freezing. 2.6. Plasmids, transfection and the Elk-1 activity luciferase assay
The plasmid pSG-GalElk-1 (fusion of the dimerization domain of the transcription factor Elk-1 and the DNA-binding domain of the yeast transcription factor Gal4) (Kortenjann et al., 1994 ) was a kind gift from Dr. Peter E. Shaw (Queen's Medical Centre, Nottingham, UK), pGL3 G5 E4 Δ38 (5 × Gal4 binding site controlling firefly luciferase expression) (Kamano et al., 1995) from Dr. Karl-Heinz Klempnauer (Westfälische-Wilhelms-Universität Münster, Germany) via Drs. Peter E. Shaw and Michael J. Courtney (Turku Centre for Biotechnology, Turku, Finland), and pRL-TK (Renilla luciferase under herpes simplex virus thymidine kinase promoter) from Promega (Madison, WI, USA); empty pUC18 plasmid was used to make the DNA amount optimal for transfection.
Transient transfection was used for the Elk-1 activity assay in CHOhOX 1 and -hOX 2 cells. Cells on 96-well plates were grown to 40% confluence and transfected in Ham's F-12 with 0.312 mg/cm 2 DNA and 0.74 ml/cm 2 FugeneHD (Roche, Mannheim, Germany). The optimized transfection conditions used for DNA were 0.6% (w/v) pSG-GalElk-1, 50% pGL3 G5 E4 D38, 10.8% pRL-TK, and 38.6% of pUC18. Five hours after transfection the cells were washed and changed to serum-free medium to serum-starve the cells overnight. The following day, the cells were stimulated in fresh serum-free medium. The inhibitors (U0126, TCS 1102, UBO-QIC) were added to the cells together with orexin -A or Nag 26. After 5 h of stimulation, the cells were lysed, collected into Eppendorf tubes and frozen. The assay was then continued according to the instructions of the manufacturer of the assay kit (Dual-Luciferase Reporter Assay system; Promega). Luminescence was measured with GloMax 20/20 luminometer (Promega). The Elk-1-specific signal (firefly luciferase) was normalized to the Renilla luciferase signal in each sample; however, since the orexin receptor stimulation increased even the Renilla luciferase expression (or activity; maximally two-fold), all the results were adjusted to the average of the Renilla luciferase signals not to underestimate the stimulation magnitude.
Cell viability and death
Cells were seeded on black, clear bottom 96-well plates 4 × 10 3 per
well. The cells were cultured overnight and treated the following day. Staining and quantitation was done 72 h later. The cells were stained with Hoechst (10 µM), YO-PRO (0.1 µM) and PrestoBlue® (0.1 µM) for 25 min at 37°C. Hoechst stains all nuclei, and is in this assay a measure of total cell number. YO-PRO has been suggested to can only stain apoptotic and not necrotic cells, but our experience is that it rather works as propidium iodide, i.e. staining cells with already some membrane damage, though maybe a bit earlier than propidium iodide (unpublished). Essentially, it is a measure necrosis (primary or secondary). PrestoBlue contains essentially non-fluorescent resazurin that is reduced in live mitochondria to red fluorescent resorufin, and is thus a measure of cell viability. Fluorescence was read using FlexStation 3 at the wavelengths 352 nm/455 nm (Hoechst), 480 nm/515 nm (YO-PRO) and 550/590 nm (PrestoBlue).
Data analysis
Each experiment was performed in triplicate (adenylyl cyclase activity, Elk-1 luciferase assay) or quadruplicate (Ca 2+ , phospholipase C activity, cell viability/death). All the data presented are summarized from several batches of cells (number given by n) unless specifically indicated to be data from a single experiment (Fig. 1AB) ; the averaged data are presented as mean ± S.E.M. Student's non-paired (Fig. 6AC) or paired ( Fig. 6A ) two-tailed t-test with Bonferroni correction for multiple comparisons was used for all statistical comparisons. Significances are as follows: ns (not significant; P > 0.05), * P < 0.05, * * P < 0.01, * ** P < 0.001; NS and the symbol † are used in the same way for the 
n h is the co-operativity (Hill) coefficient. Eq. (1) was used for fitting of all concentration-response data ( Fig. 6 ; Table S1 , in reverse version for Fig. S1 ). Eq. (2) was used only for the alternative curve-fitting of the Elk-1 data (Elk-1 alt.) for Nag 26 ( Fig. 7 ; Table S1 ). In this fitting, the inhibitory component clearly seen to cause the bell-shape of the Nag 26 concentration-response curve of OX 2 (Figs. 3 and 7 ) was assumed to be the same for both OX 1 and OX 2 and fitted according to the equation for uncompetitive inhibition. The maximum stimulatory responses were also assumed to be equal for both receptor subtypes (see Fig. 7 ). Please observe that this is does not aim at a mechanistic explanation of the apparent inhibition but simply represents a way of including the inhibition in the equation. Other ways of modelling the inhibition gave similar results.
Results
Both orexin-A and Nag 26 caused robust Ca 2+ response in orexin receptor-expressing CHO cells (Fig. 1AB) . The maximum response was equal for both ligands (Figs. 1CD and 6; Table S1), while orexin-A was clearly more potent (Figs. 1CD and 6; Table S1 ). Nag 26 showed some selectivity; when normalized to orexin-A, it had 17.6 ± 5.4-fold (n = 7) higher potency for OX 2 than for OX 1 (Fig. 6) . The response to Nag 26 could be concentration-dependently inhibited by TCS 1102 (Fig.  S1 ), and only high Nag 26 concentrations produced a minute response in the ctrl CHO cells not expressing orexin receptors (Fig. S2) . Nag 26 response in orexin receptor-expressing CHO cells was nearly fully inhibited by 1 µM of the G q/11 inhibitor UBO-QIC (Fig. S3 ). Phospholipase C activation is one of the calcium-elevating mechanisms of orexin receptors, and also reflects the G q/11 -coupling of orexin receptors in CHO cells (Kukkonen, 2016a) . However, the phospholipase C response is not as easily saturated as the Ca 2+ response, and thus may better indicate the actual efficacies of the ligands. As reported earlier (Kukkonen, 2016b; Turku et al., 2017) , orexin-A stimulation robustly activated phospholipase C ( Fig. 2AB ; Table S1 ). Nag 26 was also a strong activator, but did not quite reach the level of orexin-A (at least not for OX 1 ) (Figs. 2AB and 6; Table S1 ). Nag 26, again, indicated selectivity for OX 2 over OX 1 based on the potency (28.8 ± 2.7 fold, n = 6; normalized to orexin-A), and it also showed slightly higher maximum response for OX 2 (Figs. 2AB and 6; Table S1 ). Even saturating Nag 26 responses were inhibited by 10 µM TCS 1102 as well as by 1 µM UBO-QIC (Fig. S3) . Both orexin-A and Nag 26 caused significant responses in the Elk-1 luciferase reporter assay (Fig. 3) . Elk-1 is activated by extracellular signal-regulated kinase 1/2 (ERK1/2) but also by other mitogen-activated protein kinases (MAPKs); the involvement of ERK in the Nag 26 response was verified by the fact it was inhibited by 3 µM U0126, an inhibitor of the upstream activator of ERK1/2, MAPK/ERK kinase 1 (Fig. S3) , as previously shown for orexin-A (Jäntti et al., 2013) . The response was also specific to orexin receptors and dependent on the G q pathway, as it was fully inhibited by 10 µM TCS 1102 and 1 µM UBO-QIC, respectively (Fig. S3) . Interestingly, the concentration-response curves for Nag 26, especially for OX 2 , were bell-shaped, i.e. the Fig. 2 . Phospholipase C response to orexin-A and Nag 26 in OX 1 (A) and OX 2 (B) receptor-expressing cells. n = 5. Fig. 3 . Elk-1 driven luciferase activity in response to orexin-A and Nag 26 in OX 1 (A) and OX 2 (B) receptor-expressing cells. n = 5.
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response started decreasing after 10 µM (Fig. 3) . Adenylyl cyclase has been suggested to be regulated by orexin receptors via at least three different pathways in CHO cells, i.e. inhibition via G i and stimulation via G s and protein kinase C (Holmqvist et al., 2005; Kukkonen, 2016a, b) . The analysis is difficult, as there are no highly efficient inhibitors for the G i and G s pathways and possibly also because there are other components, as suggested recently (Kukkonen, 2016a) . In cells treated with pertussis toxin and GF1092203X, in which the G i and protein kinase C responses should be eliminated, both orexin-A and Nag 26 stimulated adenylyl cyclase activity ( Fig. 4AB; Table S1 ), though the efficacy of Nag 26 was rather low. Interestingly, Nag 26 produced an apparently equal stimulation in both OX 1 -and OX 2 -expressing cells, while orexin-A was a much better stimulant of adenylyl cyclase via OX 1 receptors than Nag 26 (Fig. 4AB) . In cells treated with cholera toxin and GF109203X, the protein kinase C response is eliminated and adenylyl cyclase saturated with Gα s , and thus inhibition of adenylyl cyclase activity can be monitored (Holmqvist et al., 2005; Kukkonen, 2016a, b) . Both orexin-A and Nag 26 inhibited the adenylyl cyclase activity (Fig. 4CD) , though the response to orexin-A was lower than previously reported (Kukkonen, 2016b) . The maximum response to Nag 26 was even lower than that to orexin-A (Fig. 4CD) , and the determination of the EC 50 value was not reliable. Both adenylyl cyclase stimulation and inhibition by Nag 26 were inhibited by TCS 1102 (Fig. S3) .
Orexin receptor stimulation has been reported to reduce the growth and induce programmed cell death in CHO cells as well as other cell types (Introduction), possibly via the G q pathway. We have also recently reported that the small molecule orexin receptor agonist, Yan 7874, induces orexin receptor-independent necrotic cell death (Turku et al., 2017) . We thus wanted to assess the ability of Nag 26 to induce cell death in our orexin receptor-expressing CHO cells. In the current study, 100 nM orexin-A caused a rather weak reduction in total (Hoechst; Fig. 5A ) and viable (PrestoBlue/Hoechst; Fig. 5B ) cell number and increase in cell death in OX 1 receptor expressing (YoPro/Hoechst; Fig. 5C ) cells, and the response was even weaker in OX 2 receptor-expressing cells (Fig. 5A-C) . Ctrl CHO cells not expressing orexin receptors did not respond to 100 nM orexin-A (Fig. 5A-C) . Nag 26 at low concentrations gave a small increase in the total cell number but at the same time a reduction in the cell viability (Fig. 5D-F) . At higher concentrations, Nag 26 led to a decrease in the total (Hoechst) and viable (PrestoBlue/Hoechst) cell numbers and an increase in cell death (YoPro/Hoechst), but similar responses were also partially seen in the control cells (Fig. 5D-F) , suggesting that it was not fully orexin receptor-specific. The orexin receptor-independent cell death-promoting compounds staurosporin and thapsigargin, used as a control, caused a much stronger reduction in cell number and increase in cell death (Fig. S4) .
Discussion
In the current study, we assess the properties of Nag 26, one of the hit molecules of a promising series of small molecule orexin receptor agonists (Nagahara et al., 2015) . The other hit molecule is compound 30/31 a.k.a. YNT-185 which is more water-soluble than Nag 26 but also slightly less potent in the Ca 2+ elevation assay than Nag 26 (Nagahara et al., 2015; Irukayama-Tomobe et al., 2017) . It is somewhat unclear, which compound -if any of these two -is more interesting for development of orexin receptor agonists; YNT-185 is apparently not lipidsoluble enough to enter the brain (Irukayama-Tomobe et al., 2017) while the higher lipid solubility of Nag 26 (Nagahara et al., 2015) might make it better suited in this respect -though this has not been tested thus far. As concerns the Ca 2+ elevation, we can largely verify the results of the previous study (Nagahara et al., 2015) , though the selectivity of Nag 26 for OX 2 is about 20-fold, which is somewhat lower than the previously reported 70-fold. It should be noted that the potencies in cells lines expressing OX 1 and OX 2 receptors at different levels cannot be directly compared, but the selectivity should be analyzed with respect to a "standard" ligand, e.g. orexin-A, as done here. In such comparison of the values in (Nagahara et al., 2015) , the selectivity is reduced from 70-to 47-fold. Remarkably, Nag 26 is reported to be only 23-fold less potent than orexin-A for OX 2 receptors in (Nagahara et al., 2015) , while we consequently found it to be about 100-fold less potent with respect to both Ca 2+ and phospholipase C responses (Table S1 ).
For the phospholipase C activation, which like Ca 2+ elevation relies on G q , the potencies of both orexin-A and Nag 26 were lower than for Ca 2+ elevation. This is expected as Ca 2+ elevation is usually strongly amplified/blunted (i.e. has a larger receptor reserve), leading to a left-shift of the concentration-response curve. The difference in potency between orexin-A and Nag 26 was nevertheless nearly the same as for the Ca 2+ response, as expected, as also is the selectivity for OX 2 . It is also interesting to note that the maximum response of Nag 26 is nearly the same as that of orexin-A; the conclusion can be drawn from the phospholipase C assay which is not assumed to be significantly blunted (Turku et al., 2016) . Thus, Nag 26 is a nearly full agonist for the G q response via both orexin receptors, unlike any previously described non-peptide ligand. It might be expected that a gene promoter activity reporter assaysuch as our apparently third G q -dependent response, Elk-1-dependent firefly luciferase expression -would be easily saturated, as there could be several limiting steps in the cascade. However, that does not seem to be the case, at least for orexin receptors in CHO cells; in contrast, the Elk-1 response shows a wide dynamic range (Jäntti et al., 2013; current study) . For Nag 26, the Elk-1 response is perplexing, as it seems to decrease again at high Nag 26 concentrations, at least for OX 2 . One possibility is that this response is orexin receptor-independent and possibly reflects the loss of cell viability at high Nag 26 concentrations. However, it is also possible that Nag 26, at high concentrations, activates another signal transduction pathway that either directly or indirectly, i.e. by reducing the receptor response towards Elk-1 or the receptor number, counteracts the Elk-1 response. The time the receptors are stimulated by the agonists is much higher in the Elk-1 assay (5 h) than in the Ca 2+ (2 min), phospholipase C (30 min) or adenylyl cyclase (10 min) assays, and thus there is time for slower processes to act as well. As this is not seen with orexin-A, this would imply that the Elk-1 response to Nag 26 displays biased agonism with respect to orexin-A. We did not investigate this further, as this takes place around the limit of Nag 26 solubility, and thus is difficult to assess and also of little interest. However, we simulated the first alternative, i.e. that Elk-1 response is determined by an orexin receptor-dependent stimulation and orexin receptor-independent inhibition, and that even the OX 1 response is blunted by this. We thus additionally fitted the Nag 26 data for Elk-1 assuming the same non-specific response-decreasing component at high Nag 26 concentration for both receptors (Eq. (2)). The results are presented in Fig. 7 and Table S1 . The data can be very well described by such an equation; even the measured values from the additional experiments with 70 µM Nag 26, which are not used for the fitting, make a very good match (Fig. 7) . The curve-fitting values obtained for OX 1 are much better in line with the results from Ca 2+ and phospholipase C assays ( Fig. 6C ; Table S1 ). It seems possible that even the phospholipase C responses for OX 1 and OX 2 are blunted in the same way around 30 µM Nag 26 (see Fig. 2 ). However, it should be stressed that the lack of solubility of Nag 26 limits assessment of the response at even higher concentration, leaving this curve-fitting model speculative.
As concerns the read-outs for G i and G s responses, it is difficult to draw firm conclusions due to weak responses to Nag 26 for the adenylyl cyclase inhibition assay (G i ) and the weak responses to Nag 26 on both receptors and even to orexin-A on OX 2 in the adenylyl cyclase stimulation assay (G s ). As we have shown before (Holmqvist et al., 2005; Kukkonen, 2016b) , the potency of even orexin-A is low for the G s response in these cells, and thus the receptor reserve and amplification of the response may be rather non-existing. In addition, the possible bellshape -as seen in the Elk-1 assay -may also be present in this response and distort the result. It is thus not possible to judge, whether the maximum response to Nag 26 indeed is much lower than that to orexin-A in OX 1 cells. The orexin receptor-specific cell death response to Nag 26 is not very prominent. However, there is some response in OX 2 -expressing cells, and as even the response to orexin-A is very weak, it would be worthwhile to test Nag 26 and YNT-185 in those primary cancer cells and cancer cell lines in which the anti-proliferative and pro-apoptotic responses to orexin receptor stimulation with orexin-A/B are prominent (Rouet-Benzineb et al., 2004; Voisin et al., 2006 Voisin et al., , 2011 .
In conclusion, the studies indicate that Nag 26 is a potent and nearly full agonist of orexin receptors, at least for the G q response, but that its potency is yet far from the potency of orexin-A. The studies also point out at some, though not prominent, biased agonism; the strongest indication of this is for OX 2 , for which the difference in potency between orexin-A and Nag 26 is much lower for the Elk-1 assay than for the Ca 2+ and phospholipase C assays. As compared to the previously reported ligand, Yan 7874 (Turku et al., 2017) , Nag 26 appears to have little detrimental, orexin receptor-independent activity, though some is seen at high concentrations. 
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Appendix A. Supplementary material
Supplementary data associated with this article can be found in the online version at doi:10.1016/j.ejphar.2018.09.003. Fig. 6 . Summary of the curve-fitting analyses of the concentration-response data for the different assays (also presented in Table S1 ). No error bars are seen for the data which was normalized to 100% (orexin-A in A) or for which the curve fitting was performed with averaged data (A-D; see Table S1 ). (A) The maximum responses to the ligands. The responses were normalized to the orexin-A response separately for each receptor subtype. The first comparison (Nag 26) is to the corresponding orexin-A response and the second comparison of the Nag 26 phospholipase C and Elk-1 responses to the Nag 26 Ca 2+ response. Table S1 ). Fig. 7 . Curve-fitting of all the Nag 26 responses according to Eq. (2). Both curves were fitted at the same time and the values of response max , K i′ , and n h2 were kept equal for OX 1 and OX 2 . These fitted values are response max(OX1) = response max(OX2) = 120%, K i′(OX1) = K i′(OX2) = 30.4 µM, and n h2(OX1) = n h2(OX2) = 2.16, and the other values are EC 50(OX1) = 75 400 µM, EC 50(OX2) = 230 µM, n h1(OX1) = 0.56, and n h1(OX2) = 1.96. n = 5, except for 70 µM Nag 26 which represent only single determinations and have not been used for the curve-fitting.
